Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3, multi-center, randomized, double-blind, placebo-controlled, 52-week study to evaluate the efficacy and safety of belimumab (HGS1006, Lymphostat-B), a fully human monoclonal anti-BLyS [LymphoStat-B; Human Genome Sciences] antibody, in subjects with systemic lupus erythematosus (SLE)

Trial Profile

A phase 3, multi-center, randomized, double-blind, placebo-controlled, 52-week study to evaluate the efficacy and safety of belimumab (HGS1006, Lymphostat-B), a fully human monoclonal anti-BLyS [LymphoStat-B; Human Genome Sciences] antibody, in subjects with systemic lupus erythematosus (SLE)

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Oct 2018

At a glance

  • Drugs Belimumab (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Biomarker; Registrational; Therapeutic Use
  • Acronyms BLISS-52
  • Sponsors Human Genome Sciences
  • Most Recent Events

    • 24 Oct 2018 Results presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
    • 24 Oct 2018 Results presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
    • 24 Oct 2018 Results (n=1684) of this and BLISS-76 trials assessing efficacy of belimumab treatment in systemic lupus erythematosus (SLE), presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top